# Comparative Analysis of the ELISIO-HX and Xevonta-Hi Dialyzers in Standard Hemodialysis

**Authors:** Blanca Villacorta Linaza, Mario Román Cabezas, María Cristina Sánchez-Pozo, María Paz Alcaide Lara, Rocío Cabra-Rodríguez, Francisco Javier Toro Prieto

PMC · DOI: 10.3390/life15040596 · 2025-04-03

## TL;DR

This study compares two dialyzers in standard hemodialysis, finding both effective for removing uremic molecules without significant differences.

## Contribution

The novel comparison of MCO and HF dialyzers in standard hemodialysis, rather than OL-HDF, is a new clinical insight.

## Key findings

- Both dialyzers showed excellent clearance of small and middle molecules with no significant efficacy differences.
- Minimal losses of albumin and total protein were observed with both dialyzers.
- Moderate reductions in serum amyloid A, placental growth factor, and interleukin-6 were noted.

## Abstract

As chronic kidney disease (CKD) prevalence rises, optimizing hemodialysis remains essential. While online hemodiafiltration (OL-HDF) is the gold standard, expanded hemodialysis (HDx), i.e., using high-performance dialyzers in standard hemodialysis, remains the most common clinical practice. Medium cutoff (MCO) membranes aim to enhance middle-molecule removal while preserving protein selectivity, although most studies evaluate them in OL-HDF. To this end, this study aims to compare the Xevonta-Hi (B. Braun), a high-flux (HF) polysulfone dialyzer, and the ELISIO-HX (Nipro), an MCO polyethersulfone dialyzer, in standard hemodialysis. In a prospective, observational study, seven stable patients sequentially received treatment with each dialyzer over four weeks. Pre- and post-dialysis levels of small and middle uremic molecules and inflammatory markers—including procalcitonin, prolactin, serum amyloid A, placental growth factor, interleukin-6, haptoglobin, ceruloplasmin, transferrin, prealbumin, and C-reactive protein—were measured. Both dialyzers demonstrated excellent clearance of small and middle molecules, with no significant differences in efficacy. Albumin and total protein losses remained minimal. Moderate reductions in serum amyloid A, placental growth factor, and interleukin-6 were observed, while no significant reductions occurred in the remaining inflammatory markers. These findings support the safety and effectiveness of both MCO and HF dialyzers in standard hemodialysis.

## Linked entities

- **Proteins:** LOC100189571 (uncharacterized LOC100189571), PROLACTIN (PROLACTIN protein), IL6 (interleukin 6), Tsf2 (transferrin 2), Ttr (transthyretin)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, CP (ceruloplasmin) [NCBI Gene 1356] {aka AB073614, CP-2}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}
- **Diseases:** inflammatory (MESH:D007249), CKD (MESH:D051436), uremic (MESH:D006463)
- **Chemicals:** polysulfone (MESH:C017662), polyethersulfone (MESH:C022840)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12028760/full.md

---
Source: https://tomesphere.com/paper/PMC12028760